The COLONPREV trial - Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening

Title: Colonoscopy versus fecal immunochemical testing

Design: Multicenter randomized, controlled noninferiority trial

Objective: Is fecal immunochemical testing (FIT) every 2 years noninferior to colonoscopy in terms of reduction of colorectal cancer mortality?


Year of publication: 2012

Inclusion Criteria: FIT, every 2 years (n=26,703) vs Colonoscopy, one time (n=26,599)

Comparison groups: AF ablation (n=203) vs amiodarone (n=203)

Primary Outcome:

  • Risk reduction in colorectal cancer deaths. Analysis expected to be performed in 2021, after 10 years of follow-up

Secondary Outcome:

  • Detection of colorectal cancer 0.1% vs 0.1% P=0.99
  • adverse outcomes bleeding, hypotension, bradycardia, or perforation 0.1% vs 0.5% P<0.001

Conclusion: Subjects in the FIT group were more likely to participate in screening than were those in the colonoscopy group. the numbers of subjects in whom colorectal cancer was detected were similar in the two study groups Source: N Engl J Med 2012; 366:697-706 | Quintero E, et al. |